A Phase II Study of INVAC-1 as Treatment of Patients With High-risk Chronic Lymphocytic Leukemia
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Mar 2018
At a glance
- Drugs HTERT DNA vaccine Invectys (Primary) ; Ibrutinib
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Invectys
- 06 Mar 2018 Last checked against ClinicalTrials.gov record.
- 27 Feb 2018 Planned initiation date changed from 1 Dec 2017 to 1 May 2018.
- 19 Dec 2017 According to a PharmaJet media release, the company has received US FDA approval to proceed with this trial.